Axsome Therapeutics Company Leadership
| AXSM Stock | USD 126.79 0.52 0.41% |
Axsome Therapeutics employs about 683 people. The company is managed by 9 executives with a total tenure of roughly 8 years, averaging almost 0.0 years of service per executive, having 75.89 employees per reported executive. Analysis of Axsome Therapeutics' management performance can provide insight into the firm performance.
Axsome |
Axsome Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2728) % which means that it has lost $0.2728 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.3163) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Axsome Therapeutics Workforce Comparison
Axsome Therapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 8,332. Axsome Therapeutics holds roughly 683 in number of employees claiming about 8% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.74) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.52) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.52. Axsome Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Axsome Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Axsome Therapeutics Notable Stakeholders
An Axsome Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Axsome Therapeutics often face trade-offs trying to please all of them. Axsome Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Axsome Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Herriot MD | Founder, Chairman and CEO | Profile | |
| Mark Jacobson | Senior Director - Operations | Profile | |
| MB CPA | Director Finance | Profile | |
| Hunter Esq | General Secretary | Profile | |
| Amanda PharmD | Senior Development | Profile | |
| Lori MBA | Executive Development | Profile | |
| Kevin PharmD | Ex Strategy | Profile | |
| Mark MA | Chief Officer | Profile | |
| Ari Maizel | Executive Commercial | Profile |
About Axsome Therapeutics Management Performance
The success or failure of an entity such as Axsome Therapeutics often depends on how effective the management is. Axsome Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Axsome management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Axsome management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.
Axsome Therapeutics Workforce Analysis
Traditionally, organizations such as Axsome Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Axsome Therapeutics within its industry.Axsome Therapeutics Manpower Efficiency
Return on Axsome Therapeutics Manpower
| Revenue Per Employee | 564.7K | |
| Revenue Per Executive | 42.9M | |
| Net Loss Per Employee | 420.5K | |
| Net Loss Per Executive | 31.9M | |
| Working Capital Per Employee | 373.3K | |
| Working Capital Per Executive | 28.3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.